00:56:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.


2023-04-17 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50
2021-12-15 22:41:33

Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") published on 15 December 2021 regarding a contemplated private
placement of new shares in the Company (the "Private Placement").

The Company is pleased to announce today that it has raised approx. NOK 50
million in gross proceeds through the Private Placement by issuance of 915,000
new shares in the Company (the "New Shares"), at a price per New Share of NOK 55
(the "Subscription Price"). The Private Placement took place through an
accelerated bookbuilding process managed by SpareBank 1 Markets AS (the
"Manager") after close of markets on 15 December 2021. The Private Placement was

The net proceeds from the Private Placement will be used to fund commercial
activities related to bringing the Hand Disinfection and Wound Irrigation
Solution to the European and the US market as well as finalization of phase 1
development of the Infection Remover (BE) and for general corporate purposes.

Allocation to investors and payment instructions are expected to be communicated
on or about 16 December, and the settlement in the Private Placement is expected
to be on or about 20 December 2021 (DVP). Settlement of the New Shares will be
made by delivery of existing and unencumbered shares in the Company that are
already listed on Euronext Growth Oslo to be lent from Dinge Invest AS (the
"Share Lender") by the Manager pursuant to a share lending agreement between the
Manager, the Company and the Share Lender (the "Share Loan"). Accordingly, the
shares delivered to the investors will be tradable from allocation.

The Share Loan will be settled by the Manager with new shares in the Company,
which has been resolved by the board of directors of the Company (the "Board")
pursuant to an authorization granted by the Company's annual general meeting on
13 April 2021.

Following registration of the share capital increase pertaining to the Private
Placement with the Norwegian Register of Business Enterprises, the Company will
have a share capital of NOK 201,669.36, divided into 10,083,468 shares, each
with a par value of NOK 0.02.

In relation to the Private Placement, Almhaug Bolig AS has exercised its right
to convert NOK 10 million of its short-term unsecured interest-free loan, with a
principal amount of NOK 15 million, into new shares in the Company at a
conversion price of NOK 38.55 per share in accordance with the loan agreement
between the Company and Almhaug Bolig AS dated 13 October 2021 (the "Debt
Conversion"). The subscription price per share was agreed in the loan agreement
based on the volume weighted average share price in the days prior to the loan
was granted on 13 October 2021. The Debt Conversion is subject to completion of
the Private Placement and resolution by the Company's extraordinary general
meeting to issue the new shares in a share capital increase by way of conversion
of debt, scheduled to be held on or about 29 December 2021 (the "EGM").

Subject to satisfaction of the conditions for completion of the Private
Placement, the Board has resolved to propose that the EGM resolves to authorize
the Board to carry out a subsequent offering of up to 218,000 new shares (the
"Subsequent Offering") towards the Company's shareholders as of 15 December 2021
(as documented by the shareholder register in the Norwegian Central Securities
Depository (VPS) as of 17 December 2021, the "Record Date") who were not
allocated shares in the Private Placement and who are not resident in a
jurisdiction where such offering would be unlawful or, for jurisdictions other
than Norway, would require any prospectus, filing, registration or similar
action ("Eligible Shareholders").

The subscription price in the Subsequent Offering will be the same as the
Subscription Price in the Private Placement, i.e. NOK 55 per share. The
Subsequent Offering will be conditional, inter alia, on (a) completion of the
Private Placement, (b) approval of the authorization of the Board for the
Subsequent Offering by the Company's shareholders at the EGM, and (c)
publication of an offer prospectus by the Company. Whether the Subsequent
Offering will ultimately be completed, will also depend on the development of
the price of the shares in the Company after completion of the Private Placement
and the Debt Conversion. The Company will issue a separate stock exchange notice
with further details on the Subsequent Offering when finally resolved.

Advokatfirmaet Wiersholm AS is acting as legal advisor to the Company in
connection with the Private Placement.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or

CFO Kristine Rød of SoftfOx Solutions AS

Mail: ir@soft-ox.com

Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Important information

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures. The securities referred to in this announcement
have not been and will not be registered under the U.S. Securities Act of 1933,
as amended (the "Securities Act"), and accordingly may not be offered or sold in
the United States absent registration or an applicable exemption from the
registration requirements of the Securities Act and in accordance with
applicable U.S. state securities laws. The Company does not intend to register
any part of the offering in the United States or to conduct a public offering of
securities in the United States. Any sale in the United States of the securities
mentioned in this announcement will be made solely to "qualified institutional
buyers" as defined in Rule 144A under the Securities Act. In any EEA Member
State, this communication is only addressed to and is only directed at qualified
investors in that Member State within the meaning of the EU Prospectus
Regulation, i.e., only to investors who can receive the offer without an
approved prospectus in such EEA Member State. The expression "EU Prospectus
Regulation" means Regulation (EU) 2017/1129 as amended (together with any
applicable implementing measures in any Member State. This communication is only
being distributed to and is only directed at persons in the United Kingdom that
are (A) (i) persons who have professional experience, knowledge and expertise in
matters relating to investments and are "investment professionals" for the
purposes of article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth
entities and other persons falling within Article 49(2)(a) to (d) of the Order
and (iii) persons to whom it may otherwise lawfully be communicated